Journals / Türk Oftalmoloji Dergisi / 2015 / Cilt: 45 - Sayı: 4

Diagnosis, Follow-Up and Treatment Results in Thyroid Ophthalmopathy

Tiroid Oftalmopatide Tanı, İzlem ve Tedavi Sonuçlarımız

Pages
156–163
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Older age and high thyroid receptor antibody titer were correlated with disease activity (p=0.031 and p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: To discuss our follow-up and treatment results in thyroid-associated ophthalmopathy (TAO).Ma te ri als and Met hods: The records of 168 TAO cases who were followed at our clinic between October 1998 and October 2013 were reviewed retrospectively.
📊
Key Findings & Data:The severity and activity of the disease were evaluated according to the criteria of the European Group on Graves’ Ophthalmopathy (EUGOGO) and Clinical Activity Score (CAS).Re sults: Sixty-three men and 105 women participated in the study.
💡
Conclusion & Impact:Older age and high thyroid receptor antibody titer were correlated with disease activity (p=0.031 and p
🔬Design:Review & Systematic Survey
📍Scope:2013 Verileri
⚙️Variables:Domain Parameters

Abstract

Objectives: To discuss our follow-up and treatment results in thyroid-associated ophthalmopathy (TAO).Ma te ri als and Met hods: The records of 168 TAO cases who were followed at our clinic between October 1998 and October 2013 were reviewed retrospectively. The severity and activity of the disease were evaluated according to the criteria of the European Group on Graves’ Ophthalmopathy (EUGOGO) and Clinical Activity Score (CAS).Re sults: Sixty-three men and 105 women participated in the study. The mean age of the patients was 42.3±12.4 years. Smoking habit was noted in 54.2% of the cases. Graves’ disease was the most common (80.4%) thyroid pathology accompanying TAO. TAO was mild in 64.4%, moderate-to-severe in 33.6% and severe in 2% of the eyes. Male gender was found as an independent risk factor for severity of the disease (p=0.040). TAO was in the active phase in 32.6% of the eyes. Older age and high thyroid receptor antibody titer were correlated with disease activity (p=0.031 and p

Özet

Amaç: Tiroid oftalmopatide izlem ve tedavi sonuçlarımızı tartışmak.Ge reç ve Yön tem: Ekim 1998-Ekim 2013 tarihleri arasında kliniğimizde takip edilen 168 tiroid oftalmopati olgusunun dosyaları retrospektif olarak incelendi. Hastalığın şiddeti ve aktivitesi sırasıyla European Group on Graves' Ophthalmopathy (EUGOGO) ve Klinik Aktivite Skorlaması (KAS) kriterlerine göre değerlendirildi. Bulgular: Çalışmaya alınan 168 olgunun 105'i kadın, 63'ü erkekti. Olguların yaş ortalaması 42,3±12,4 yıldı. Olguların %54,2'sinde sigara kullanım öyküsü mevcuttu. Graves hastalığı tiroid oftalmopatiye eşlik eden en sık (%80,4) tiroid patolojisiydi. Gözlerin %64,4'ünde hafif, %33,6'sında orta-ciddi ve %2'sinde ciddi tutulum saptandı. Erkek cinsiyet hastalığın şiddeti için bağımsız risk faktörü olarak bulundu (p=0,040). Tiroid oftalmopati gözlerin %32,6'sında aktif fazdaydı. İleri yaş ve yüksek tiroid reseptör antikor titreleri hastalığın aktivitesi ile ilişkiliydi (sırasıyla p=0,031 ve p

🔖

Cite This Article

GÜNDÜZ, K., SAVKU, E. (2022). Diagnosis, Follow-Up and Treatment Results in Thyroid Ophthalmopathy. Türk Oftalmoloji Dergisi, Cilt: 45 - Sayı: 4, 156–163. https://ajindex.com/articles/637957

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Cozma I, Cozma LS, Boyce RL, Ludgate ME, Lazarus JH, Lane CM. Variation in thyroid status in patients with Graves’ orbitopathy. Acta Endo. (Buc) 2009;5:191-198
  2. Spitzweg C, Joba W, Hunt N, Heufelder AE. Analysis of human thyrotropin receptor gene expression and immunoreactivity in human orbital tissue. Eur J Endocrinol. 1997;136:599-607
  3. Crisp MS, Lane C, Halliwell M, Wynford-Thomas D, Ludgate M. Thyrotropin receptor transcripts in human adipose tissue. J Clin Endocrinol Metab. 1997; 82:2003-2005
  4. Eckstein A, Esser J, Mann K, Schott M. Clinical value of TSH receptor antibodies measurement in patients with Graves’ orbitopathy. Pediatr Endocrinol Rev. 2010;7:198-203
  5. Lytton SD, Ponto KA, Kanitz M, Matheis N, Kohn LD, Kahaly GJ. A novel thyroid stimulating immunoglobulin bioassay is a functional indicator of activity and severity of Graves’ orbitopathy. J Clin Endocrinol Metab. 2010;95:2123-2131
  6. Tallstedt L, Lundell G, Tørring O, Wallin G, Ljunggren JG, Blomgren H, Taube A. Occurrence of ophthalmopathy after treatment for Graves’ hyperthyroidism. The Thyroid Study Group. N Engl J Med. 1992;326:1733- 1738
  7. Bartalena L, Marcocci C, Bogazzi F, Manetti L, Tanda ML, Dell’Unto E, Bruno-Bossio G, Nardi M, Bartolomei MP, Lepri A,Rossi G, Martino E, Pinchera A. Relation between therapy for hyperthyroidism and the course of Graves’ ophthalmopathy. N Engl J Med. 1998;338:73-78
  8. Prummel MF, Bakker A, Wiersinga WM, Baldeschi L, Mourits MP, Kendall-Taylor P, Perros P, Neoh C, Dickinson AJ, Lazarus JH, Lane CM, Heufelder AE, Kahaly GJ, Pitz S, Orgiazzi J, Hullo A, Pinchera A, Marcocci C, Sartini MS, Rocchi R, Nardi M,Krassas GE, Halkias A. Multi-center study on the characteristics and treatment strategies of patients with Graves’ orbitopathy: the first European Group on Graves’ Orbitopathy experience. Eur J Endocrinol. 2003;148:491-495
  9. Bartalena L, Baldeschi L, Dickinson A, Eckstein A, Kendall-Taylor P, Marcocci C, Mourits M, Perros P, Boboridis K, Boschi A,Currò N, Daumerie C, Kahaly GJ, Krassas GE, Lane CM, Lazarus JH, Marinò M, Nardi M, Neoh C, Orgiazzi J, Pearce S,Pinchera A, Pitz S, Salvi M, Sivelli P, Stahl M, von Arx G, Wiersinga WM; European Group on Graves’ Orbitopathy (EUGOGO). Consensus statement of the European Group on Graves’ orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol. 2008;158:273-285
  10. Sasim IV, Berendschot TT, van Isterdael C, Mourits MP. Planning health care for patients with Graves’ orbitopathy. Graefes Arch